vTv Therapeutics Inc.
VTVT
Positions held
Your positionsVTVT isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $118.93M | Enterprise value | $287.09M | Trailing P/E | — | Forward P/E | -6.40 |
| PEG | — | Price / book | 4.75 | Beta | 0.21 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 22.2% | Operating margin | -25.1% |
| Profit margin | -12.9% | ROE | -15.8% | ROA | -10.1% | Debt / equity | — |
| Current ratio | 12.48 | Free cash flow | $674,375 | Analyst recommendation | strong_buy | Mean target | $54.71 |
| 52w high | $44.00 | 52w low | $19.50 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $36.8M | $0.0M | $0.0M | $0.0M |
| Op margin | — | 63.1% | — | — | — |
| Net income | -$13.1M | $24.1M | -$7.1M | -$8.7M | -$6.0M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$13.9M | $23.3M | -$7.9M | -$10.7M | -$7.7M |
- Revenue -100% vs prior quarter ($0 vs $37M).
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $1.0M | $0.0M | $2.0M |
| Op margin | — | -2377.6% | — | -1116.9% |
| Net income | -$27.0M | -$18.5M | -$20.3M | -$19.2M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$32.8M | -$24.2M | -$25.5M | -$22.5M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · vTv Therapeutics stock jumps on FDA orphan drug status
2026-10-07 · VTv Therapeutics Gets FDA Orphan Drug Designation for Sickle Cell Candidate
2026-10-07 · vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease
2026-10-05 · vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)
2026-09-15 · vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-09-02 · vTv Therapeutics to Participate in September Investor Conferences
2026-08-19 · vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-08-06 · VTv Therapeutics: Q2 Earnings Snapshot
2026-08-06 · vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-07-28 · vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Price (daily)
Full chart · RSI · MACD · patterns